Lv3
208 积分 2021-12-13 加入
Incidence, mortality, and survival associated with acute leukaemia subtypes by age group in China: a population-based cancer registry analysis and cohort study
13天前
已完结
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study
2个月前
已完结
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis
4个月前
已完结
Systemic immunoglobulin light chain amyloidosis
4个月前
已完结
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
4个月前
已完结
Pharmacokinetics of Venetoclax, a Novel BCL‐2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non‐Hodgkin Lymphoma
4个月前
已完结
Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy
4个月前
已完结
Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
6个月前
已完结
Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
6个月前
已完结
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study
7个月前
已完结
皖公网安备34019202002308
